[4] The FDA label also provides guidance on when to consider discontinuation: if a patient has not lost at least 5% of their initial body weight after 12 weeks on the 2.4 mg dose, stopping treatment may be appropriate as further benefits are unlikely
The trials main goal was to evaluate the percentage of patients showing complete resolution of MASH without liver fibrosis worsening after 52 weeks of treatment
Glutathione, when effective at all, may take 4-6 months to show results that often fade after discontinuation
This creates maximum precision for small doses, making it ideal for microdosing protocols or researchers who prioritize measurement accuracy above all else
A secondary analysis of the STEP-HFpEF and STEP-HFpEF DM trials involving 1145 obese T2DM-associated HFpEF patients showed that semaglutide reduced NT-proBNP levels and improved health status after 52 weeks [83]
These observations have been hypothesized to be due to a higher medication exposure among women, i.e., increased plasma concentration of the treatment due to their lower mean body weight